Correlating Quantitative Fecal Immunochemical Test Results with Neoplastic Findings on Colonoscopy in a Population-Based Colorectal Cancer Screening Program: A Prospective Study

Table 2

Fecal immunochemical test performance by test cut-off.

	≥10 μg/g; (≥50 ng/mL); (/%)	≥15 μg/g; (≥75 ng/mL); (/%)	≥20 μg/g; (≥100 ng/mL); (/%)	≥40 μg/g; (≥200 ng/mL); (/%)	≥100 μg/g; (≥500 ng/mL); (/%)
CRC	449 (2.3)	409 (3.1)	388 (3.8)	344 (5.7)	242 (8.4)
Missed CRC	—	40 (8.9)	61 (13.6)	105 (23.4)	207 (46.1)
HRA	4012 (20.4)	3176 (24.4)	2712 (26.9)	1911 (31.6)	1109 (38.4)
Missed HRA	—	836 (20.8)	1300 (32.4)	2101 (52.4)	2903 (72.4)
MLRA	1173 (6.0)	772 (5.9)	584 (5.8)	321 (5.3)	132 (4.6)
LRA	5029 (25.6)	3172 (24.4)	2359 (23.4)	1247 (20.6)	474 (16.4)
All neoplasia	10663 (54.2)	7529 (57.8)	6043 (59.9)	3823 (63.2)	1957 (67.8)
CSPY saved	—	6641 (33.8)	9571 (48.7)	13615 (69.3)	16773 (85.3)
Total results	19660	13019	10089	6045	2887

CRC, colorectal cancer; CSPY, colonoscopy; HRA, high-risk adenoma; LRA, low-risk adenoma; MLRA, multiple low-risk adenomas.